Infectious Diseases

304 A probiotic yeast-based immunotherapy against Clostridioides difficile infection.

303 Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments.

302 Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies.

301 Speech can produce jet-like transport relevant to asymptomatic spreading of virus.

300 Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.

299 Hydroxychloroquine is not useful against SARS-CoV-2 infection in non-human primates.

298 A network-based explanation of why most COVID-19 infection curves are linear.

297 The nucleotide analogue prodrug remdesivir reduces viral load and lung disease in a rhesus macaque model of SARS-CoV-2 infection.

296 Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

295 Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications.

294 COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis.

293 The implications of silent transmission for the control of COVID-19 outbreaks.

292 Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.

291 Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.

290 Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.

289 Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.

288 Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children.

287 A mobile app, the COVID Symptom Study, offers data on risk factors, early symptoms, clinical outcomes, and geographical hotspots.

286 Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.

285 Remdesivir for the Treatment of Covid-19 — Preliminary Report.

Free Images for Presentation: sunipix SUNIPIX